These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1509 related articles for article (PubMed ID: 22396395)

  • 1. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors.
    Morsch M; Reddel SW; Ghazanfari N; Toyka KV; Phillips WD
    Exp Neurol; 2012 Oct; 237(2):286-95. PubMed ID: 22789393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis.
    Plomp JJ; Huijbers MG; van der Maarel SM; Verschuuren JJ
    Ann N Y Acad Sci; 2012 Dec; 1275():114-22. PubMed ID: 23278586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia.
    Niks EH; Kuks JB; Wokke JH; Veldman H; Bakker E; Verschuuren JJ; Plomp JJ
    Muscle Nerve; 2010 Aug; 42(2):283-8. PubMed ID: 20544919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.
    Viegas S; Jacobson L; Waters P; Cossins J; Jacob S; Leite MI; Webster R; Vincent A
    Exp Neurol; 2012 Apr; 234(2):506-12. PubMed ID: 22326541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis.
    Mori S; Kubo S; Akiyoshi T; Yamada S; Miyazaki T; Hotta H; Desaki J; Kishi M; Konishi T; Nishino Y; Miyazawa A; Maruyama N; Shigemoto K
    Am J Pathol; 2012 Feb; 180(2):798-810. PubMed ID: 22142810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Myasthenia gravis induced by autoantibodies against MuSK].
    Shigemoto K; Konishi T; Ohta M
    Nihon Rinsho; 2008 Jun; 66(6):1149-54. PubMed ID: 18540361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody.
    Punga AR; Flink R; Askmark H; Stålberg EV
    Muscle Nerve; 2006 Jul; 34(1):111-5. PubMed ID: 16453324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
    Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
    Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis.
    Reddel SW; Morsch M; Phillips WD
    Curr Opin Neurol; 2014 Oct; 27(5):558-65. PubMed ID: 25159928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The auto-antigen repertoire in myasthenia gravis.
    Vrolix K; Fraussen J; Molenaar PC; Losen M; Somers V; Stinissen P; De Baets MH; Martínez-Martínez P
    Autoimmunity; 2010 Aug; 43(5-6):380-400. PubMed ID: 20380581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis.
    Mori S; Shigemoto K
    Autoimmun Rev; 2013 Jul; 12(9):912-7. PubMed ID: 23537506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-fiber electromyography during menstrual exacerbation and ovulatory suppression in MuSK antibody-positive myasthenia gravis.
    Stickler DE; Stickler LL
    Muscle Nerve; 2007 Jun; 35(6):808-11. PubMed ID: 17221882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seronegative myasthenia gravis.
    Vincent A; McConville J; Farrugia ME; Newsom-Davis J
    Semin Neurol; 2004 Mar; 24(1):125-33. PubMed ID: 15229799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Autoantibodies in myasthenia gravis].
    Motomura M; Narita Masuda T
    Brain Nerve; 2013 Apr; 65(4):433-9. PubMed ID: 23568991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis.
    Mori S; Yamada S; Kubo S; Chen J; Matsuda S; Shudou M; Maruyama N; Shigemoto K
    J Neuroimmunol; 2012 Mar; 244(1-2):1-7. PubMed ID: 22222307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pathogenic antibodies in myasthenia gravis].
    Motomura M
    Brain Nerve; 2010 Apr; 62(4):411-8. PubMed ID: 20420182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathogenic mechanisms of myasthenia gravis induced by antibodies against muscle-specific kinase].
    Maruyama N; Shigemoto K
    Rinsho Shinkeigaku; 2007 Nov; 47(11):842-4. PubMed ID: 18210813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.